News

October 16, 2024

Apollo appoint Dr Dipender Gill to the strategic advisory board

Dr Dipender Gill has joined Apollo Therapeutics strategic advisory board, bringing with him extensive knowledge and experience in leveraging human-centric evidence within drug discovery and development.

Dr Gill is a world-leading expert in genetic epidemiology including Mendelian randomization techniques.

More News

05 - 05 - 2025

Apollo Therapeutics marks World Pulmonary Hypertension Day with update on the clinical development of APL-9796 (anti-ZIP12 mAb) for the treatment of Pulmonary Hypertension

View Article

01 - 08 - 2025

Apollo appoints new Special Advisor, Dr Husseini Manji

View Article

11 - 12 - 2024

Apollo Therapeutics Signs Exclusive Ex-China License From Sunshine Lake Pharma for Clinical-Stage FGF21 / GLP-1 Dual Receptor Agonist, a Therapeutic With Major Commercial Potential in Multiple Indications

View Article

All News